Nutriband Secures FDA Engagement for Abuse-Deterrent Fentanyl Patch Development

Nutriband Inc. (NASDAQ: NTRB), a transdermal pharmaceutical developer, has secured crucial FDA engagement for its lead abuse-deterrent technology through an approved Type C Meeting for AVERSA™ Fentanyl. The September 18 meeting with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine will focus on Chemistry, Manufacturing, and Controls plans spanning the entire development and commercialization timeline. This regulatory milestone addresses the complete development arc from Investigational New Drug submission through 505(b)(2) New Drug Application approval.

The 505(b)(2) regulatory pathway allows Nutriband to leverage existing fentanyl safety data while focusing regulatory review specifically on the novel abuse-deterrent components of its technology. This approach potentially accelerates the development process by building upon previously established safety profiles while introducing new protective features. The FDA's engagement signals agency recognition of the product's potential to address critical unmet medical needs in the opioid abuse prevention space.

AVERSA™ technology represents a significant advancement in transdermal drug delivery systems, designed to be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The technology's application to fentanyl patches is particularly important given the high abuse potential of this powerful opioid analgesic. For more information about the company's technology platform, visit https://www.Nutriband.com.

The development comes at a critical time when opioid abuse remains a major public health concern, with transdermal fentanyl patches being particularly vulnerable to misuse through extraction and injection methods. Regulatory agencies have been actively seeking technological solutions to address this problem, making Nutriband's progress particularly significant for both medical and regulatory communities. The successful development of abuse-deterrent formulations could substantially impact how potent opioids are prescribed and managed in clinical practice.

Investors and industry observers can follow the company's progress through its newsroom at https://ibn.fm/NTRB, which provides ongoing updates about development milestones and regulatory advancements. The upcoming FDA meeting represents a crucial step in validating the company's development strategy and manufacturing approach for bringing this important technology to market.